HighTower Advisors’s Scinai Immunotherapeutics SCNI Stock Holding History

HighTower Advisors’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-18	Closed	-$701K	–	2781
2020 Q3	$701K	Sell	18 -1	-5%	-$38.4K	﹤0.01%	1399
2020 Q2	$435K	Hold	19	–	–	﹤0.01%	1533
2020 Q1	$146K	Buy	19 +2	+12%	+$17.7K	﹤0.01%	1877
2019 Q4	$157K	Hold	17	–	–	﹤0.01%	2024
2019 Q3	$96K	Hold	17	–	–	﹤0.01%	2169
2019 Q2	$97K	Hold	17	–	–	﹤0.01%	2164
2019 Q1	$91K	Hold	17	–	–	﹤0.01%	2078
2018 Q4	$81K	Hold	17	–	–	﹤0.01%	1988
2018 Q3	$94K	Hold	17	–	–	﹤0.01%	2065
2018 Q2	$112K	Hold	17	–	–	﹤0.01%	1993
2018 Q1	$91K	Hold	17	–	–	﹤0.01%	1983
2017 Q4	$91K	Buy	+17	New	+$107K	﹤0.01%	2047

Other funds holding SCNI

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

GRP

Global Retirement Partners San Rafael, California $6.54B AUM

HighTower Advisors's SCNI Position: Q4 2020 in Review

HighTower Advisors sold out of Scinai Immunotherapeutics (SCNI) in Q4 2020, closing a stake of 18 shares — an estimated $701K sold.

HighTower Advisors first reported a position in SCNI in Q4 2017 and held it in 12 quarters. The position peaked at $701K in Q3 2020. 10 funds tracked by Wall St. Rank hold SCNI as of Q4 2020.

HighTower Advisors reported no remaining Scinai Immunotherapeutics position as of Q4 2020 after selling out during the quarter.
HighTower Advisors sold 18 Scinai Immunotherapeutics shares in Q4 2020, an estimated $701K.
HighTower Advisors first reported a position in Scinai Immunotherapeutics in Q4 2017 and held it in 12 quarters.
HighTower Advisors's Scinai Immunotherapeutics position peaked at $701K in Q3 2020.
10 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q4 2020.

Based on HighTower Advisors's 13F filing for Q4 2020, filed 10 Feb 2021.